干细胞移植与再生障碍性贫血治疗

www.yongyao.net　　2009-11-11 12:07:13　　来源：　　责任编辑：

分享到：

6 参考文献
1 Brodsky RA, Jones RJ.Aplastic anaemia. Lancet 2005;365(9471):1647-1656
2 Bacigalupo A.Aplastic anemia: pathogenesis and treatment.Hematology Am Soc Hematol Educ Program 2007;2007:23-28
3 Nakao S. Physiopathology of and therapy for aplastic anemia. NipponNaika Gakkai Zasshi 2006;95(9):1851-1857
4 Young NS.Pathophysiologic mechanisms in acquired aplastic anemia.Hematology Am Soc Hematol Educ Program 2006; 72-77
5 Kojima S. Treatment of acquired a plastic anemia: an update. RinshoKetsueki 2004;45(3):202-208
6 Okamoto S.Treatment outcome of hematopoietic stem cell transplantation for aplastic anemia. Nippon Naika Gakkai Zasshi2005;94(7):1309-15
7 Trigg ME.Hematopoietic stem cells. Pediatrics 2004;113(4Suppl):1051-1057
8 Schrezenmeier H, Bredeson C, Bruno B, et al. Comparison ofallogeneic bone marrow and peripheral blood stem cell transplantation for aplastic anemia: collaborative study of European Blood and Marrow Transplant Group (EBMT) and International Bone Marrow Transplant Registry (IBMTR). Blood 2003;102:267
9 Mao P, Zhu Z, Wang H,et al.Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur JHaematol 2005;75(5):430-435
10 Redei I, Waller EK, Holland HK, et al.Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilizedperipheral stem cell transfusions. Bone Marrow Transplant
1997;19(2):175-177
11 Gomez JR, Garcia MJ, Serrano J, et al.Chimerism analysis in long-term survivor patients after bone marrow transplantation for severe aplastic anemia. Haematologica 1997;82(5):588-591
12 Horowitz MM.Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000;37(1):30-42
13 Passweg JR, Pérez WS, Eapen M,et al.Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia.Bone Marrow Transplant 2006;37(7):641-649
14 Storb R, Longton G, Anasetti C, et al.Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transplant 1992;10Suppl 1:45-52
15 Territo MC.Autologous bone marrow repopulation following high dose cyclophosphamide and allogeneic marrow transplantation in aplastic anaemia. Br J Haematol 1977;36(3):305-12
16 Brodsky RA, Sensenbrenner LL, Smith BD, et al.Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med2001;135(7):477-83
17 McCann SR, Bacigalupo A, Gluckman E, et al.Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European
Bone Marrow Transplant Group. Bone Marrow Transplant 1994;13(3):233-237
18 Gale RP, Ho W, Feig S, et al.Prevention of graft rejection following bone marrow transplantation. Blood 1981;57(1):9-12
19 Champlin RE, Horowitz MM, van Bekkum DW, et al.Graft failure following bone marrow transplantation for severe aplastic anemia:risk factors and treatment results. Blood 1989;73(2):606-613
20 Gluckman E, Horowitz MM, Champlin RE,et al.Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome.Blood 1992;79(1):269-275
21 Smith BR, Guinan EC, Parkman R, et al.Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia. Transplantation 1985;39(6):671-673
22 Ades L, Mary JY, Robin M, et al.Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004;103(7):2490-2497
23 Kahl C, Leisenring W, Deeg HJ,et al.Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 2005;130(5):747-51
24 Resnick IB, Aker M, Shapira MY, et al.Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol 2006;133(6):649-654
25 Gupta V, Ball SE, Yi QL, et al.Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from
HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004;10(12):867-876
26 Kim HJ, Park CY, Park YH,et al.Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant 2003;31(2):79-86
27 Passweg JR, Pérez WS, Eapen M,et al.Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia.Bone Marrow Transplant 2006;37(7):641-649
28 Deeg HJ, ODonnell M, Tolar J,et al.Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood
2006;108(5):1485-91
29 Bacigalupo A, Locatelli F, Lanino E,et al.Fludarabine,cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant2005;36(11):947-50
30 Kojima S, Matsuyama T, Kato S,et al.Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood2002;100(3):799-803